Next Article in Journal
Associations of miR-181a with Health-Related Quality of Life, Cognitive Functioning, and Clinical Data of Patients with Different Grade Glioma Tumors
Previous Article in Journal
Heterogeneous Evolution of Sex Chromosomes in the Torrent Frog Genus Amolops
Previous Article in Special Issue
The Novel Protein ADAMTS16 Promotes Gastric Carcinogenesis by Targeting IFI27 through the NF-κb Signaling Pathway
 
 
Review

Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies

1
Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA
2
Phillips Exeter Academy, Exeter, NH 03833, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Guanbin Song
Int. J. Mol. Sci. 2022, 23(19), 11145; https://doi.org/10.3390/ijms231911145
Received: 27 July 2022 / Revised: 12 September 2022 / Accepted: 20 September 2022 / Published: 22 September 2022
(This article belongs to the Special Issue Signal Pathways in Cancer)
Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas. View Full-Text
Keywords: Waldenström macroglobulinemia; B-cell lymphoma; non-Hodgkin’s; bone marrow microenvironment; disease progression; targeted therapy Waldenström macroglobulinemia; B-cell lymphoma; non-Hodgkin’s; bone marrow microenvironment; disease progression; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Boutilier, A.J.; Huang, L.; Elsawa, S.F. Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies. Int. J. Mol. Sci. 2022, 23, 11145. https://doi.org/10.3390/ijms231911145

AMA Style

Boutilier AJ, Huang L, Elsawa SF. Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies. International Journal of Molecular Sciences. 2022; 23(19):11145. https://doi.org/10.3390/ijms231911145

Chicago/Turabian Style

Boutilier, Ava J., Lina Huang, and Sherine F. Elsawa. 2022. "Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies" International Journal of Molecular Sciences 23, no. 19: 11145. https://doi.org/10.3390/ijms231911145

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop